BDBM538633 NCGC 00371859::US11254667, Compound I-39::US11542261, Compound I-39

SMILES COc1cc2ncc(-c3cccc(NC4CCNC4)n3)n2cc1C#N

InChI Key InChIKey=NPJRSFLHNQNUQF-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 538633   

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Children''S Hospital Medical Center

US Patent
LigandPNGBDBM538633(NCGC 00371859 | US11254667, Compound I-39 | US115...)
Affinity DataIC50: 33nMAssay Description:AlphaScreen SureFire STAT5 (pTyr694;Tyr699) Assay kit (Perkin Elmer). Assay was performed according to manufacturer protocol.More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538633(NCGC 00371859 | US11254667, Compound I-39 | US115...)
Affinity DataIC50: 33nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetGTPase NRas(Human)
Children''S Hospital Medical Center

US Patent
LigandPNGBDBM538633(NCGC 00371859 | US11254667, Compound I-39 | US115...)
Affinity DataIC50: 5.58E+3nMAssay Description:AlphaScreen SureFire STAT5 (pTyr694;Tyr699) Assay kit (Perkin Elmer). Assay was performed according to manufacturer protocol.More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetGTPase NRas(Human)
Children''S Hospital Medical Center

US Patent
LigandPNGBDBM538633(NCGC 00371859 | US11254667, Compound I-39 | US115...)
Affinity DataIC50: 5.58E+3nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent